{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:07:34Z","timestamp":1791310054001,"version":"4.3.1"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T00:00:00Z","timestamp":1455753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0145958","type":"journal-article","created":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T16:28:00Z","timestamp":1455812880000},"page":"e0145958","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1371","volume":"11","author":[{"given":"Hai-Ha","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadia","family":"El-Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Mombled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Guitarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muaamar","family":"Al-Gobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Fall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Janiaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivanny","family":"Marchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Cucherat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9odora","family":"Bejan-Angoulvant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Gueyffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,2,18]]},"reference":[{"key":"ref1","article-title":"The Heart, Arteries and Veins","author":"E Englestein","year":"1998"},{"key":"ref2","article-title":"Heart Disease: A Textbook of Cardiovascular Medicine","author":"R Myerburg","year":"1997"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/01.CIR.96.9.3215","article-title":"Sudden Death in Coronary Artery Disease Acute Ischemia Versus Myocardial Substrate","volume":"96","author":"D Mehta","year":"1997","journal-title":"Circulation"},{"key":"ref4","first-page":"9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"SA Atlas","year":"2007","journal-title":"J Manag Care Pharm JMCP"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/VHRM.S13779","article-title":"Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure","volume":"7","author":"JM Nappi","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0031-1291318","article-title":"Aldosterone and the heart: from basic research to clinical evidence","volume":"44","author":"C Catena","year":"2012","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm M\u00e9tabolisme"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/eurheartj\/ehl123","article-title":"Treatment of chronic heart failure: a comparison between the major guidelines","volume":"27","author":"J McMurray","year":"2006","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1751-7133.2011.00235.x","article-title":"Pharmacologic therapy for New York Heart Association class IV heart failure","volume":"17","author":"MA Caccamo","year":"2011","journal-title":"Congest Heart Fail Greenwich Conn"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008\u2021: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaborati","volume":"10","author":"K Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"CW Yancy","year":"2013","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"B Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"F Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"B. Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"B Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref16","unstructured":"Cochrane Risk of Bias Criteria (Appendix E) [Internet]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0049217\/\" xlink:type=\"simple\">http:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0049217\/<\/ext-link>"},{"key":"ref17","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"N MANTEL","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JPT Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"key":"ref21","article-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 510 [updated March 2011]","author":"JA Sterne"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"M Cicoira","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","article-title":"Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone","volume":"54","author":"GJ Mak","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5847\/wjem.j.issn.1920-8642.2013.01.009","article-title":"Effect of spironolactone on cardiac remodeling after acute myocardial infarction","volume":"4","author":"C-T Wu","year":"2013","journal-title":"World J Emerg Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"919.e1","DOI":"10.1016\/j.ahj.2005.03.032","article-title":"Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction","volume":"150","author":"P Di Pasquale","year":"2005","journal-title":"Am Heart J"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MCA.0b013e32833fd243","article-title":"The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction: a randomized follow-up study","volume":"21","author":"M Kayrak","year":"2010","journal-title":"Coron Artery Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","article-title":"Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction","volume":"141","author":"MG Modena","year":"2001","journal-title":"Am Heart J"},{"key":"ref28","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study","author":"G Montalescot","year":"2014","journal-title":"Eur Heart J"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/00365510902802278","article-title":"Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction","volume":"69","author":"I Uzunhasan","year":"2009","journal-title":"Scand J Clin Lab Invest"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/1755-5922.12006","article-title":"Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction?","volume":"31","author":"M.A. Vatankulu","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ahj.2009.04.001","article-title":"Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?","volume":"157","author":"RAP Weir","year":"2009","journal-title":"Am Heart J"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"F Edelmann","year":"2013","journal-title":"JAMA J Am Med Assoc"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms","volume":"364","author":"F Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MAJ.0b013e31829dd6b1","article-title":"Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms","volume":"347","author":"E. Vizzardi","year":"2014","journal-title":"Am J Med Sci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"A Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF)","volume":"17","author":"A Deswal","year":"2011","journal-title":"J Card Fail"},{"key":"ref37","first-page":"507","article-title":"A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"S Taheri","year":"2012","journal-title":"Saudi J Kidney Dis Transplant Off Publ Saudi Cent Organ Transplant Saudi Arab"},{"key":"ref38","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"S Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transplant Off Publ Saudi Cent Organ Transplant Saudi Arab"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","article-title":"Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction","volume":"3","author":"JE Udelson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"ref40","first-page":"22","article-title":"Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions","volume":"36","author":"MA Munger","year":"2011","journal-title":"P T Peer-Rev J Formul Manag"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4065\/80.12.1623","article-title":"Aldosterone receptor antagonists in the medical management of chronic heart failure","volume":"80","author":"WHW Tang","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCHEARTFAILURE.112.000074","article-title":"Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"X Li","year":"2013","journal-title":"Circ Heart Fail"},{"key":"ref43","first-page":"1693","article-title":"Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials","volume":"98","author":"D Phelan","year":"2012","journal-title":"Heart Br Card Soc"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials","volume":"30","author":"JA Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/bcp.12012","article-title":"Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis","volume":"75","author":"L Hu","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/CIRCHEARTFAILURE.112.000003","article-title":"Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"SR Bapoje","year":"2013","journal-title":"Circ Heart Fail"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-014-0261-8","article-title":"Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials","volume":"13","author":"Y Chen","year":"2015","journal-title":"BMC Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ejhf.13","article-title":"Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction","volume":"16","author":"H Clark","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy: Results From the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"P Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/chf.12011","article-title":"When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?","volume":"19","author":"S Bangalore","year":"2013","journal-title":"Congest Heart Fail Greenwich Conn"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2710.2003.00491.x","article-title":"The safety of spironolactone treatment in patients with heart failure","volume":"28","author":"C Anton","year":"2003","journal-title":"J Clin Pharm Ther"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1527-5299.2003.02397.x","article-title":"Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism","volume":"9","author":"DA Sica","year":"2003","journal-title":"Congest Heart Fail Greenwich Conn"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/CIRCHEARTFAILURE.111.965160","article-title":"Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial","volume":"5","author":"E O\u2019Meara","year":"2012","journal-title":"Circ Heart Fail"},{"key":"ref54","article-title":"Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure","author":"R Rossi","year":"2013","journal-title":"J Renin-Angiotensin-Aldosterone Syst JRAAS"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjmed.2011.12.018","article-title":"Eplerenone is not superior to older and less expensive aldosterone antagonists","volume":"125","author":"S Chatterjee","year":"2012","journal-title":"Am J Med"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2007.03.062","article-title":"Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure","volume":"50","author":"AKY Chan","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","article-title":"Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure","volume":"13","author":"X Gao","year":"2007","journal-title":"J Card Fail"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2010.06.052","article-title":"Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class i or II heart failure","volume":"106","author":"E. Vizzardi","year":"2010","journal-title":"Am J Cardiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0145958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T14:50:07Z","timestamp":1567608607000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0145958"}},"subtitle":[],"editor":[{"given":"C. Mary","family":"Schooling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,18]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0145958","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726155351.793515453","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,18]]}}}